Who
Matthew R. Henn
Officer
Company insider
Files Form 4 as: Officer, Seres Therapeutics.
In numbers
- Trades disclosed
- 93
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $2.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 26 Jan 2020
- Last trade
- 17 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 18 Aug 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $36981 at $4.55 | filing |
| 17 Aug 2026filed 18 Aug 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $36981 at $4.55 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —238 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —140 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —140 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —98 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —98 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —238 | filing |
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $58077 at $7.53 | filing |
| 18 May 2026filed 19 May 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $58077 at $7.53 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —238 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —141 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —141 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —97 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —97 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —238 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
News
Critical Contrast: Seres Therapeutics (NASDAQ:MCRB) & BioLineRx (NASDAQ:BLRX)MCRB · tickerreport.com · 21 Oct 2026MDxHealth (NASDAQ:MDXH) versus Seres Therapeutics (NASDAQ:MCRB) Financial ComparisonMCRB · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name Matthew R. Henn; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.